Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction

Abstract For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment ele...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aline Klassen, Andrea Tedesco Faccio, Carolina Raissa Costa Picossi, Priscilla Bento Matos Cruz Derogis, Carlos Eduardo dos Santos Ferreira, Aline Soriano Lopes, Alessandra Sussulini, Elisa Castañeda Santa Cruz, Rafaela Tudela Bastos, Stefanie Caroline Fontoura, Antonio Martins Figueiredo Neto, Marina Franco Maggi Tavares, Maria Cristina Izar, Francisco Antonio Helfenstein Fonseca
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/bda4510dc88b4ad1b0efc021c38160fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bda4510dc88b4ad1b0efc021c38160fa
record_format	dspace
spelling	oai:doaj.org-article:bda4510dc88b4ad1b0efc021c38160fa2021-12-02T16:35:18ZEvaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction10.1038/s41598-021-95455-z2045-2322https://doaj.org/article/bda4510dc88b4ad1b0efc021c38160fa2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-95455-zhttps://doaj.org/toc/2045-2322Abstract For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg QD or simvastatin 40 mg combined with ezetimibe 10 mg QD for 30 days. Fasting blood samples were collected on the first day (D1) and after 30 days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Similar classic lipid profile was obtained in both groups of lipid-lowering therapies. However, differences with the lipidomic analysis were observed between D30 and D1 for most of the analyzed classes. Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin. Correlation studies between classic lipid profiles and lipidomic results showed different information. These findings seem relevant, due to the involvement of these lipid classes in crucial mechanisms of atherosclerosis, and may account for residual cardiovascular risk. Randomized clinical trial: ClinicalTrials.gov, NCT02428374, registered on 28/09/2014.Aline KlassenAndrea Tedesco FaccioCarolina Raissa Costa PicossiPriscilla Bento Matos Cruz DerogisCarlos Eduardo dos Santos FerreiraAline Soriano LopesAlessandra SussuliniElisa Castañeda Santa CruzRafaela Tudela BastosStefanie Caroline FontouraAntonio Martins Figueiredo NetoMarina Franco Maggi TavaresMaria Cristina IzarFrancisco Antonio Helfenstein FonsecaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Aline Klassen Andrea Tedesco Faccio Carolina Raissa Costa Picossi Priscilla Bento Matos Cruz Derogis Carlos Eduardo dos Santos Ferreira Aline Soriano Lopes Alessandra Sussulini Elisa Castañeda Santa Cruz Rafaela Tudela Bastos Stefanie Caroline Fontoura Antonio Martins Figueiredo Neto Marina Franco Maggi Tavares Maria Cristina Izar Francisco Antonio Helfenstein Fonseca Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
description	Abstract For cardiovascular disease prevention, statins alone or combined with ezetimibe have been recommended to achieve low-density lipoprotein cholesterol targets, but their effects on other lipids are less reported. This study was designed to examine lipid changes in subjects with ST-segment elevation myocardial infarction (STEMI) after two highly effective lipid-lowering therapies. Twenty patients with STEMI were randomized to be treated with rosuvastatin 20 mg QD or simvastatin 40 mg combined with ezetimibe 10 mg QD for 30 days. Fasting blood samples were collected on the first day (D1) and after 30 days (D30). Lipidomic analysis was performed using the Lipidyzer platform. Similar classic lipid profile was obtained in both groups of lipid-lowering therapies. However, differences with the lipidomic analysis were observed between D30 and D1 for most of the analyzed classes. Differences were noted with lipid-lowering therapies for lipids such as FA, LPC, PC, PE, CE, Cer, and SM, notably in patients treated with rosuvastatin. Correlation studies between classic lipid profiles and lipidomic results showed different information. These findings seem relevant, due to the involvement of these lipid classes in crucial mechanisms of atherosclerosis, and may account for residual cardiovascular risk. Randomized clinical trial: ClinicalTrials.gov, NCT02428374, registered on 28/09/2014.
format	article
author	Aline Klassen Andrea Tedesco Faccio Carolina Raissa Costa Picossi Priscilla Bento Matos Cruz Derogis Carlos Eduardo dos Santos Ferreira Aline Soriano Lopes Alessandra Sussulini Elisa Castañeda Santa Cruz Rafaela Tudela Bastos Stefanie Caroline Fontoura Antonio Martins Figueiredo Neto Marina Franco Maggi Tavares Maria Cristina Izar Francisco Antonio Helfenstein Fonseca
author_facet	Aline Klassen Andrea Tedesco Faccio Carolina Raissa Costa Picossi Priscilla Bento Matos Cruz Derogis Carlos Eduardo dos Santos Ferreira Aline Soriano Lopes Alessandra Sussulini Elisa Castañeda Santa Cruz Rafaela Tudela Bastos Stefanie Caroline Fontoura Antonio Martins Figueiredo Neto Marina Franco Maggi Tavares Maria Cristina Izar Francisco Antonio Helfenstein Fonseca
author_sort	Aline Klassen
title	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
title_short	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
title_full	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
title_fullStr	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
title_full_unstemmed	Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
title_sort	evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/bda4510dc88b4ad1b0efc021c38160fa
work_keys_str_mv	AT alineklassen evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT andreatedescofaccio evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT carolinaraissacostapicossi evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT priscillabentomatoscruzderogis evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT carloseduardodossantosferreira evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT alinesorianolopes evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT alessandrasussulini evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT elisacastanedasantacruz evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT rafaelatudelabastos evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT stefaniecarolinefontoura evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT antoniomartinsfigueiredoneto evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT marinafrancomaggitavares evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT mariacristinaizar evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction AT franciscoantoniohelfensteinfonseca evaluationoftwohighlyeffectivelipidloweringtherapiesinsubjectswithacutemyocardialinfarction
_version_	1718383715914088448

Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction

Ejemplares similares